Participated · Equity · Apr 2021

CeQur commercializes simple-to-use, wearable insulin-delivery devices designed to replace multiple daily injections, with CeQur Simplicity as its mealtime insulin patch offering. The company reports clinical evidence showing significantly improved A1C and time-in-range outcomes and cites studies and presentations supporting patient adherence. Adoption is expanding across primary care and endocrinology practices; the company says better than 85% of claims are covered as a pharmacy benefit with an average copay of less than $45 per month. Nearly 90% of patients reported better adherence with CeQur Simplicity versus multiple daily injections, according to cited patient-experience data. CeQur has new FDA clearances and an advancing pipeline that includes extended 7-day wear and 1-unit and 2-unit patch options. The company announced a $100 million Series E to fund commercial expansion, including growth of its field sales organization.